Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

DRMA

Dermata Therapeutics Inc

Jun 18 • 04:00PM ET

1.17

-0.16 -12.03 %

Healthcare • Biotechnology • USA • Nano • NASD

Peers: LNAI APRE BCDA BIVI CALC CVM GOVX KAPA KPRX NEUP

Index	-	P/E	-	EPS (ttm)	-5.31	Insider Own	32.71%	Shs Outstand	4.02M	Perf Week	-4.10%
Market Cap	4.71M	Forward P/E	-	EPS next Y	-1.52	Insider Trans	0.08%	Shs Float	2.71M	Perf Month	-0.85%
Enterprise Value	-2.24M	PEG	-	EPS next Q	-0.55	Inst Own	2.65%	Short Float	3.56%	Perf Quarter	-3.31%
Income	-7.10M	P/S	-	EPS this Y	72.92%	Inst Trans	-14.44%	Short Ratio	0.12	Perf Half Y	-49.57%
Sales	0.00M	P/B	0.73	EPS next Y	31.22%	ROA	-81.31%	Short Interest	0.10M	Perf YTD	-49.57%
Book/sh	1.59	P/C	0.68	EPS next 5Y	-	ROE	-103.58%	52W High	8.00 -85.38%	Perf Year	-83.14%
Cash/sh	1.73	P/FCF	-	EPS past 3/5Y	84.25% 61.24%	ROIC	-110.75%	52W Low	1.10 6.36%	Perf 3Y	-99.58%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.47% 7.06%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	93.30%	Oper. Margin	-	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.00	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	44.51	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.09	EPS Q/Q	89.29%	SMA20	-6.29%	Beta	0.65	Target Price	4.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-7.06%	Rel Volume	0.15	Prev Close	1.33
Employees	9	LT Debt/Eq	0.00	Earnings	May 13 AMC	SMA200	-52.07%	Avg Volume	786.95K	Price	1.17
IPO	Aug 13, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	9.43% -	Trades		Volume	121,506	Change	-12.03%

May-13-26 04:05PM	Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 (ACCESSWIRE)
Apr-02-26 08:30AM	Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System (ACCESSWIRE) +7.50%
Mar-26-26 05:15PM	Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025 (ACCESSWIRE) -6.16% -13.87%
Mar-10-26 08:30AM	Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing (ACCESSWIRE)
Mar-05-26 09:00AM	Dermata Opens a New Chapter with the Release of Tome Skincare (ACCESSWIRE)
08:05AM	Loading…
Jan-20-26 08:05AM	Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office (ACCESSWIRE) -5.65%
Dec-29-25 04:05PM	Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +22.58%
Dec-24-25 08:00AM	Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +16.18%
Dec-04-25 08:00AM	A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity (ACCESSWIRE) -16.28%
Nov-14-25 04:05PM	Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results (ACCESSWIRE) -7.49%
Oct-02-25 08:00AM	Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office (ACCESSWIRE)
Sep-17-25 01:00AM	Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025 (ACCESSWIRE) -5.50%
Sep-10-25 08:00AM	Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments (ACCESSWIRE) +5.97%
Aug-13-25 05:00PM	Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results (ACCESSWIRE) +5.48% -9.85%
Jul-08-25 08:00AM	Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis (ACCESSWIRE) -9.35%
09:00AM	Loading…
May-14-25 09:00AM	Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (ACCESSWIRE)
Apr-15-25 08:30AM	Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks (ACCESSWIRE)
Mar-27-25 08:15PM	Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) +5.19% -16.90%
08:00AM	BREAKING: Dermata's XYNGARI Phase 3 Trial Topline Data Meets All Primary Endpoints (PR Newswire)
Mar-17-25 04:16PM	Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results (ACCESSWIRE)
Mar-04-25 08:03AM	Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI Phase 3 STAR-1 Clinical Trial for Acne (PR Newswire)
Feb-25-25 07:58AM	Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis (ACCESS Newswire) -6.67%
Jan-29-25 04:05PM	Dermata to Present on BioPub on January 31, 2025 (ACCESSWIRE)
Jan-23-25 04:15PM	Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +12.26%
Jan-22-25 08:00AM	Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -16.54%
Jan-21-25 08:00AM	Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R) (ACCESS Newswire)
Dec-16-24 09:00AM	Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM) (ACCESSWIRE)
Dec-10-24 09:00AM	Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne (ACCESSWIRE)
Dec-03-24 09:00AM	Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne (ACCESS Newswire)
Nov-15-24 08:35AM	Life Sciences Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) -5.79%
04:15PM	Loading…
Nov-13-24 04:15PM	Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (ACCESSWIRE)
Nov-12-24 08:35AM	Life Sciences Investor Forum Agenda Announced for November 14th (GlobeNewswire)
Nov-11-24 08:35AM	Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024 (GlobeNewswire)
Oct-08-24 04:15PM	Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024 (ACCESSWIRE)
Sep-17-24 05:15PM	Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -11.21% +9.22%
Sep-16-24 09:00PM	Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +46.84%
Sep-05-24 04:05PM	Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 (ACCESSWIRE) -5.30% +10.49%
Aug-07-24 11:53PM	DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q2 2024 (InvestorPlace) +12.45%
04:05PM	Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (ACCESSWIRE)
Jul-17-24 09:00AM	Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne (ACCESSWIRE)
May-17-24 08:30AM	Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -19.23%
May-15-24 10:54PM	DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.05%
04:05PM	Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (ACCESSWIRE)
May-13-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) +5.94%
Apr-03-24 07:00AM	Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now (GlobeNewswire)
Apr-02-24 07:00AM	Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now (GlobeNewswire)
Mar-27-24 04:05PM	Dermata to Present at the Emerging Growth Conference on April 3, 2024 (ACCESSWIRE)
Mar-21-24 10:53PM	DRMA Stock Earnings: Dermata Therapeutics Reported Results for Q4 2023 (InvestorPlace)
04:05PM	Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results (ACCESSWIRE)
Feb-07-24 07:00AM	Presenting on the Emerging Growth Conference 67 Day 2 on February 8 Register Now (GlobeNewswire)
Feb-06-24 07:00AM	Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now (GlobeNewswire)
Feb-01-24 09:00AM	Dermata to Present at the Emerging Growth Conference on February 7, 2024 (ACCESSWIRE) -6.67%
Jan-05-24 08:31AM	Why Is Dermata Therapeutics (DRMA) Stock Up 62% Today? (InvestorPlace) +11.49%
Jan-04-24 04:05PM	Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis (ACCESSWIRE)
Dec-20-23 04:05PM	Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne (ACCESSWIRE) -7.53%
Nov-17-23 09:06AM	Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug (Zacks)
Nov-16-23 01:30PM	Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) +6.72%
08:00AM	Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols (ACCESSWIRE)
Nov-09-23 04:05PM	Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results (ACCESSWIRE) +8.57% -7.72%
Oct-26-23 09:00AM	Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial (ACCESSWIRE)
Aug-31-23 09:00AM	Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE)
Aug-10-23 04:15PM	Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results (ACCESSWIRE)
Jun-27-23 09:00AM	Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne (ACCESSWIRE)
Jun-13-23 04:15PM	Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET (ACCESSWIRE) +6.55%
Jun-08-23 09:00AM	Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results (ACCESSWIRE)
May-26-23 04:00PM	Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -13.37% -6.17%
May-24-23 08:00AM	Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -9.72%
May-11-23 04:05PM	Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results (ACCESSWIRE) +8.43% +35.23%
May-10-23 11:46AM	Dermata Therapeutics awaits FDA go-ahead for lead candidate DMT310 to enter Phase 3 studies (News Direct)
Apr-21-23 12:02PM	Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate (Zacks) -8.04%
Apr-20-23 06:00AM	Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package (ACCESSWIRE) +11.72%
Mar-20-23 04:30PM	Dermata Therapeutics Announces Closing of $5.0 Million Public Offering (ACCESSWIRE) -10.67%
Mar-16-23 01:15PM	Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering (ACCESSWIRE) -21.63%
Feb-21-23 04:05PM	Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results (ACCESSWIRE)
Dec-05-22 08:30AM	Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea (ACCESSWIRE) -59.88%
Nov-10-22 05:20PM	Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results (ACCESSWIRE) +10.36%
Sep-06-22 09:00AM	Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference (ACCESSWIRE) +15.25%
Aug-24-22 04:05PM	Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase (ACCESSWIRE)
Aug-15-22 04:05PM	Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results (ACCESSWIRE)
Jun-13-22 09:00AM	Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea (ACCESSWIRE) -5.08%
May-23-22 09:00AM	Dermata to Present at the H.C. Wainwright Global Investment Conference (ACCESSWIRE) +7.14%
May-16-22 04:05PM	Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results (ACCESSWIRE) -9.71% -7.26%
Apr-25-22 04:50PM	Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -7.69%
Apr-21-22 09:00AM	Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE)
Mar-28-22 08:30AM	Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results (ACCESSWIRE)
Mar-24-22 08:30AM	Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference (ACCESSWIRE)
Feb-10-22 07:27AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +32.71%
Feb-07-22 08:58AM	Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know (Benzinga) -34.68%
Jan-13-22 08:30AM	Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors (ACCESSWIRE)
Jan-05-22 08:30AM	Dermata to Present at the H.C. Wainwright BioConnect Conference (ACCESSWIRE) -6.43%
Nov-22-21 05:06AM	Companies Like Dermata Therapeutics (NASDAQ:DRMA) Are In A Position To Invest In Growth (Simply Wall St.) -26.89%
04:53AM	52 Biggest Movers From Friday (Benzinga)
Nov-19-21 02:17PM	Dermata's Aesthetic Improvement Candidate Fails To Impress - Read Why (Benzinga) -30.17%
08:30AM	Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions (ACCESSWIRE)
Nov-17-21 08:00AM	Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea (ACCESSWIRE)
Nov-15-21 04:01PM	Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-12-21 08:00AM	Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting (ACCESSWIRE)
Nov-11-21 06:00AM	Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Conditions (ACCESSWIRE)
Oct-19-21 07:00AM	18 Stocks Moving in Tuesday's Pre-Market Session (Benzinga)
06:53AM	Dermata Stock Jumps On Positive Psoriasis Candidate Data (Benzinga)

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.

FounderMr. Gerald T. Proehl

Co-Founder & Lead Independent DirectorMr. David F. Hale

M.B.A.Ms. Kyri K. Van Hoose CPA

Ph.D.Dr. Christopher J. Nardo M.P.H.

Associate General CounselMr. Sean Proehl

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Scott Kathleen D.	Director	Jun 16 '26	Sale	1.19	11	13	0	Jun 16 04:15 PM
Bedoya-Toro Munera Maria E	SVP, Regulatory Affairs	Feb 17 '26	Buy	1.27	1,000	1,270	1,012	Mar 17 05:44 PM

Open in Screener

SPRY

ARS Pharmaceuticals Inc

Jun 18 • 04:00PM ET

9.65

-0.25 -2.53 %

Healthcare • Biotechnology • USA • Small • NASD

SPRY ARS Pharmaceuticals Inc daily Stock Chart

Peers: HRMY SUPN ALKS PRGO BHC AMRX INDV LNTH TEVA VTRS

| Held by: XBI VTI IWM VXF IWO IBB SCHA VTWO SMLF VHT

Index	RUT	P/E	-	EPS (ttm)	-2.00	Insider Own	35.05%	Shs Outstand	99.30M	Perf Week	0.63%
Market Cap	958.28M	Forward P/E	-	EPS next Y	-0.96	Insider Trans	-0.08%	Shs Float	64.50M	Perf Month	34.59%
Enterprise Value	853.83M	PEG	-	EPS next Q	-0.48	Inst Own	74.28%	Short Float	39.53%	Perf Quarter	16.97%
Income	-197.98M	P/S	9.68	EPS this Y	-0.57%	Inst Trans	-1.01%	Short Ratio	15.35	Perf Half Y	-9.47%
Sales	98.99M	P/B	15.63	EPS next Y	45.37%	ROA	-64.39%	Short Interest	25.50M	Perf YTD	-17.17%
Book/sh	0.62	P/C	4.77	EPS next 5Y	-	ROE	-136.40%	52W High	18.90 -48.94%	Perf Year	-39.35%
Cash/sh	2.02	P/FCF	-	EPS past 3/5Y	-26.04% -12.85%	ROIC	-125.44%	52W Low	6.66 44.89%	Perf 3Y	55.14%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	300.09% -	Gross Margin	74.12%	Volatility	5.13% 6.87%	Perf 5Y	-69.73%
Dividend TTM	-	EV/Sales	8.63	EPS Y/Y TTM	-1130.30%	Oper. Margin	-204.49%	ATR (14)	0.58	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.77	Sales Y/Y TTM	1.92%	Profit Margin	-200.00%	RSI (14)	58.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.94	EPS Q/Q	-76.39%	SMA20	5.99%	Beta	0.90	Target Price	28.80
Payout	-	Debt/Eq	1.57	Sales Q/Q	184.47%	SMA50	12.67%	Rel Volume	1.37	Prev Close	9.90
Employees	163	LT Debt/Eq	1.57	Earnings	May 15 BMO	SMA200	2.83%	Avg Volume	1.66M	Price	9.65
IPO	Dec 04, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-18.22% 2.17%	Trades		Volume	2,276,961	Change	-2.53%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-26	Initiated	Northland Capital	Outperform	$25
Nov-04-25	Resumed	Roth Capital	Buy	$30
Sep-04-25	Initiated	Roth Capital	Buy	$40
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$30
Feb-10-25	Initiated	Oppenheimer	Outperform	$40
Aug-20-24	Initiated	Cantor Fitzgerald	Overweight
Aug-13-24	Upgrade	Raymond James	Outperform → Strong Buy	$18 → $22
Aug-12-24	Reiterated	Leerink Partners	Outperform	$19 → $20
Jul-25-24	Initiated	Raymond James	Outperform	$18
Mar-05-24	Upgrade	Leerink Partners	Market Perform → Outperform	$6 → $18
Feb-20-24	Upgrade	William Blair	Mkt Perform → Outperform
Sep-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Jan-31-23	Initiated	Wedbush	Outperform	$10
Jan-03-23	Initiated	William Blair	Outperform	$17
Dec-13-22	Initiated	SVB Leerink	Outperform	$14

Show Previous Ratings

Jun-04-26 08:00AM	Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies (GlobeNewswire)
May-16-26 08:30AM	ARS Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby)
May-15-26 07:01PM	ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) -6.49%
06:00AM	ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
May-13-26 08:00AM	ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President (GlobeNewswire) -7.18%
08:00AM	Loading…
May-07-26 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results (GlobeNewswire)
Apr-15-26 06:05AM	neffy (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Mar-27-26 08:00AM	ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy 1 mg (epinephrine nasal spray) Label (GlobeNewswire) -5.72%
Mar-09-26 03:01PM	ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ... (GuruFocus.com)
07:10AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
06:00AM	ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization (GlobeNewswire)
Mar-06-26 07:15AM	What To Expect From ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings (GuruFocus.com)
Mar-02-26 12:23PM	Canadian Natural to Report Q4 Earnings: What's in the Offing? (Zacks)
10:00AM	ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-23-26 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences (GlobeNewswire)
08:00AM	Loading…
Feb-10-26 08:00AM	ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting (GlobeNewswire)
Feb-02-26 01:12PM	What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment? (Benzinga)
Jan-21-26 08:00AM	California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use (GlobeNewswire)
Jan-09-26 12:32PM	Bad News For Competitor Turns Into Big Win For ARS Pharma Stock (Benzinga) +19.27%
11:28AM	Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application (Benzinga)
03:16AM	ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating (Insider Monkey)
Dec-30-25 08:10AM	ARS Pharmaceuticals announces NMPA approval for neffy 2 mg (TipRanks)
Dec-29-25 08:00AM	neffy (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Nov-26-25 08:00AM	ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-10-25 04:01PM	ARS Pharmaceuticals Inc (SPRY) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
07:05AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
06:00AM	ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) (GlobeNewswire)
Nov-07-25 07:19AM	ARS Pharmaceuticals Inc (SPRY) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +7.99%
Nov-06-25 09:10AM	Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -9.45%
Nov-05-25 09:15AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
09:35AM	Loading…
Nov-04-25 09:35AM	DraftKings, Flutter downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	ARS Pharma Launches Get neffy on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray) (GlobeNewswire)
Nov-03-25 02:23PM	UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results (GlobeNewswire)
07:45AM	ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
Oct-08-25 08:00AM	ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy (epinephrine nasal spray) (GlobeNewswire) +7.55%
Sep-29-25 04:05PM	ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy (GlobeNewswire)
Sep-19-25 08:00AM	neffy (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Sep-17-25 11:44AM	ARS Pharmaceuticals, Inc. (SPRY): A Bull Case Theory (Insider Monkey)
Sep-09-25 08:11AM	ARS Pharmaceuticals announces real-world evidence on neffy effectiveness (TipRanks)
Sep-08-25 08:00AM	Real-World Evidence Supports Clinical Effectiveness of neffy (epinephrine nasal spray) in Patients Experiencing Anaphylaxis (GlobeNewswire) +6.26%
Sep-04-25 02:54PM	ARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA (Insider Monkey)
Aug-28-25 08:00AM	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-25 08:15AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -5.04%
07:00AM	ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy (epinephrine nasal spray) (GlobeNewswire)
05:26AM	Cisco Systems headlines earnings slate (MarketWatch)
Aug-12-25 09:24AM	ARS Pharmaceuticals Inc (SPRY) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Aug-11-25 06:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -6.40%
Aug-08-25 01:56PM	Paramount, Rocket, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-04-25 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 05:35PM	Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates (Zacks)
08:50AM	Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength (Zacks)
Jul-30-25 10:00AM	Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-29-25 10:00AM	Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-18-25 12:27PM	MHRA approves needle-free adrenaline nasal spray for anaphylaxis (Pharmaceutical Technology)
09:25AM	EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Jul-15-25 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy? (Zacks)
09:55AM	Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High? (Zacks)
08:50AM	What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing' (Zacks)
Jun-15-25 05:26AM	Jim Cramer on ARS Pharmaceuticals: "It's a Great Flier" (Insider Monkey)
Jun-11-25 09:02PM	Lightning Round: I don't want to buy enterprise software right now, says Jim Cramer (CNBC TV)
May-27-25 08:00AM	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-25 03:12AM	ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Call Highlights: Strong Launch of Neffy Amid ... (GuruFocus.com)
May-14-25 10:44PM	Q1 2025 ARS Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -9.36%
08:15AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy (epinephrine nasal spray) (GlobeNewswire)
May-13-25 09:28AM	ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-08-25 05:06AM	ARS Pharmas epinephrine nasal spray 1mg now available in US (Pharmaceutical Technology)
May-05-25 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results (GlobeNewswire)
May-04-25 04:32PM	Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential (Seeking Alpha)
May-02-25 08:00AM	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abello A/S to Expand Reach of neffy (epinephrine nasal spray) to Additional U.S. Pediatricians (GlobeNewswire)
Apr-30-25 06:51AM	ARS Pharmaceuticals Has A Blockbuster Candidate (Seeking Alpha)
Apr-05-25 05:31PM	ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money (Insider Monkey)
Mar-23-25 07:18AM	Wall Street Week Ahead (SeekingAlpha)
Mar-21-25 12:16PM	Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz (TipRanks) -13.63%
12:03PM	ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
03:03AM	ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
12:40AM	Q4 2024 ARS Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 04:04PM	ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. (Investor's Business Daily) +22.83%
03:31PM	ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await (SeekingAlpha)
01:29PM	ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion (SeekingAlpha)
01:28PM	ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript (SeekingAlpha)
08:25AM	ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates (Zacks)
07:00AM	ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-06-25 05:27AM	FDA approves ARS neffy 1mg for paediatric anaphylaxis (Pharmaceutical Technology)
Mar-03-25 04:35PM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences (GlobeNewswire)
Feb-20-25 07:02PM	ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients (GlobeNewswire)
Feb-18-25 08:00AM	ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting (GlobeNewswire)
Feb-05-25 08:00AM	ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference (GlobeNewswire)
Jan-21-25 08:00AM	ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools (GlobeNewswire) +7.24%
Jan-13-25 04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily)
08:00AM	ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy (epinephrine nasal spray) (GlobeNewswire)
Jan-07-25 08:15AM	ARS Pharmaceuticals files for approval of neffy in Canada, U.K. (TipRanks)
06:43AM	ARS Pharma seeks approval for epinephrine spray in Canada and UK (Medical Device Network)
Jan-06-25 08:00AM	ARS Pharmaceuticals Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abello A/S (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abell A/S (GlobeNewswire)
Dec-19-24 05:25PM	ARS Pharmaceuticals Announces neffy (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies (GlobeNewswire)
Dec-18-24 08:00AM	ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.80%
Dec-12-24 02:32PM	ARS Pharmaceuticals Announces Filings for Approval of neffy in China, Japan and Australia (GlobeNewswire)

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

M.S.Mr. Richard E. Lowenthal M.B.A.

M.D.Dr. Sarina Tanimoto M.B.A.

Chief Business OfficerMr. Justin Chakma

PresidentMr. Donn Casale

Co-Founder & Chief Science OfficerDr. Robert Bell Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Karas Eric	Chief Commercial Officer	Jun 12 '26	Option Exercise	1.50	25,000	37,500	37,176	Jun 12 08:06 PM
Karas Eric	Chief Commercial Officer	Jun 12 '26	Sale	10.00	25,000	250,000	12,176	Jun 12 08:06 PM
Fitzpatrick Alexander A	Chief Legal Officer	Jun 12 '26	Sale	10.00	3,355	33,550	90,910	Jun 12 08:04 PM
ERIC KARAS	Officer	Jun 12 '26	Proposed Sale	10.00	25,000	250,000		Jun 12 04:31 PM
ALEXANDER FITZPATRICK	Officer	Jun 12 '26	Proposed Sale	10.00	3,355	33,550		Jun 12 04:17 PM
Dorsey Brian	Chief Operating Officer	Nov 13 '25	Option Exercise	0.64	21,828	13,970	32,617	Nov 14 06:43 PM
Dorsey Brian	Chief Operating Officer	Nov 13 '25	Sale	8.71	21,828	190,050	10,789	Nov 14 06:43 PM
Chakma Justin	Chief Business Officer	Nov 12 '25	Option Exercise	0.84	30,000	25,200	166,380	Nov 14 06:42 PM
Chakma Justin	Chief Business Officer	Nov 12 '25	Sale	8.87	166,380	1,476,147	0	Nov 14 06:42 PM
BRIAN T DORSEY	Officer	Nov 13 '25	Proposed Sale	8.71	21,828	190,050		Nov 13 04:08 PM
JUSTIN CHAKMA	Officer	Nov 12 '25	Proposed Sale	8.91	30,000	267,357		Nov 12 05:26 PM
Chakma Justin	Officer	Nov 12 '25	Proposed Sale	8.87	138,380	1,227,420		Nov 12 10:56 AM
Lowenthal Richard E	PRESIDENT AND CEO	Aug 21 '25	Sale	14.49	50,000	724,345	1,196,494	Aug 22 04:30 PM
Scott Kathleen D.	Chief Financial Officer	Aug 21 '25	Option Exercise	1.50	12,500	18,750	22,542	Aug 22 04:30 PM
Scott Kathleen D.	Chief Financial Officer	Aug 21 '25	Sale	15.00	12,500	187,500	10,042	Aug 22 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Aug 20 '25	Sale	14.09	37,656	530,626	1,247,447	Aug 21 05:36 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Aug 19 '25	Sale	14.03	12,344	173,130	1,285,103	Aug 21 05:36 PM
KATHLEEN D SCOTT	Officer	Aug 21 '25	Proposed Sale	15.00	12,500	187,500		Aug 21 04:18 PM
Lowenthal Richard E	Officer	Aug 21 '25	Proposed Sale	14.15	150,000	2,123,000		Aug 21 11:20 AM
Tanimoto Sarina	Officer	Aug 19 '25	Proposed Sale	14.00	150,000	2,100,000		Aug 19 10:22 AM
Karas Eric	Chief Commercial Officer	Jul 01 '25	Option Exercise	1.50	15,000	22,500	25,315	Jul 03 04:21 PM
Karas Eric	Chief Commercial Officer	Jul 01 '25	Sale	16.99	15,000	254,860	10,315	Jul 03 04:21 PM
Flynn James E	10% Owner	Jun 27 '25	Sale	18.46	740,149	13,663,151	4,887,254	Jul 01 04:42 PM
ERIC KARAS	Officer	Jul 01 '25	Proposed Sale	16.99	15,000	254,859		Jul 01 04:20 PM

DRMA

Dermata Therapeutics Inc

SPRY

ARS Pharmaceuticals Inc

Upgrade your Finviz experience